Background Present combination antiretroviral therapy (cART) alone does not cure HIV infection and requires lifelong drug treatment. The potential role of HIV therapeutic vaccines as part of an HIV cure is under consideration. Our aim was to assess the effi cacy, safety, and immunogenicity of Vacc-4x, a peptide-based HIV-1 therapeutic vaccine targeting conserved domains on p24
Introduction
Present combination antiretroviral therapy (cART) improves survival, enhances quality of life, and reduces the risk of onward transmission of HIV. 1, 2 However, cART alone does not cure HIV infection and requires that several drugs be taken for life. Interest in therapeutic immunisation as a means to improve immune responses has greatly increased, and, more recently, there has been interest in therapeutic immunisation as a component of viral eradication or functional-cure treatment strategies. 3, 4 There is now a pressing need to identify therapeutic vaccine candidates that show immunogenicity associated with virological control. Although trials of HIV vaccines in human beings have so far shown limited effi cacy in this regard, a recent report assessing a dendritic-cellbased vaccine did show specifi c immune responses that seemed to change plasma viral-load setpoint after cART interruption in patients with chronic HIV-1 infection treated early in the course of the disease. 5 However, the limitations of this approach are the logistics of providing personalised dendritic-cell-based vaccines to larger populations of patients, which might ultimately restrict the use of such an approach. In the ideal scenario, a broadly applicable vaccine should induce immune responses capable of controlling viral replication in at least some patients, even after discontinuation of cART.
To this end our aim was to assess the role of Vacc-4x, a peptide-based therapeutic vaccine designed to improve and sustain immune responses to conserved domains on the HIV-1 core protein p24
Gag . This rationale is based on observations that T-cell-mediated immune responses to Gag are associated with virus control and delayed disease progression. 6 The Vacc-4x peptides are modifi ed by aminoacid substitution to improve antigen processing and presentation on diverse HLAs. The domains of p24 Gag represented in Vacc-4x are largely synonymous with the conserved immunologically vulnerable sector-3 regions crucial for virus assembly, and where immune escape comes at a cost to viral fi tness. 7 Vacc-4x was safe and well tolerated in previous phase 1 and 2 clinical trials in HIV-infected participants in Norway. 8, 9 It was both immunogenic and induced durable immunological memory 10 and a transient reduction in viral load. 11 The present study is the fi rst Vacc-4x placebocontrolled trial incorporating a cART interruption phase and represents one of the largest prospective, randomised, double-blind, placebo-controlled phase 2 clinical trials for a therapeutic HIV vaccine so far.
Methods

Participants
Between July, 2008, and June, 2010, we did a randomised, double-blind, placebo-controlled, phase 2 clinical trial at 18 clinical trial sites in Germany, Italy, Spain, the UK, and the USA. The study enrolled individuals aged 18-55 years, HIV-positive for at least 1 year, virologically suppressed on cART (viral load <50 copies per mL for the past 6 months), prestudy CD4 cell count of 400 × 10⁶ cells per L or greater, and nadir (lowest ever) CD4 cell count of 200 × 10⁶ cells per L or greater. The study was planned as a phase 2b test-ofconcept study recruiting 345 participants; however, enrolment was stopped because of slow recruitment after 136 participants were randomly assigned to study groups and the study was redefi ned by the US Food and Drug Administration (FDA) as an exploratory phase 2 study for hypothesis-generating purposes. An independent data and safety monitoring board (DSMB) was formed to review safety data for the protection of participant safety. The DSMB reviewed safety data for the fi rst 20 participants enrolled into the study after the fourth primary immunisation at week 4 (or had withdrawn from study before this visit). A second safety review took place when 100 participants were enrolled, progressed past treatment completion (week 18), and were followed up until week 28 (or had withdrawn from study before this visit). The DSMB could also arrange unscheduled meetings if there were any ongoing substantial safety concerns. The study continued without the DSMB raising any safety concerns. The 52 week follow-up period was completed in June, 2010, and long-term follow-up ended in June, 2011.
This study was done in accordance with the International Conference on Harmonisation Guideline for Good Clinical Practice. All participants provided written informed consent.
Randomisation and masking
The study was double-blind with respect to treatment assignment, so the participants and investigators were unaware of the identity of the study treatment received. Pharmacists, from whom treatment allocation was not masked, prepared and distributed treatment to participants. Randomisation was stratifi ed by site, block size was three. Participants were randomly assigned (2:1) to receive either Vacc-4x or placebo. The randomisation scheme was prepared by an independent statistician and was stored securely with restricted access until any formal request to unmask study participants.
On randomisation at week 1 and subsequent entry into the treatment phase, participants were assigned a fourdigit randomisation number (fi rst two digits representing the study centre number and the fi nal two representing an incremental number for the order participants were randomly assigned to receive study treatment at the site).
Procedures
Participants were given six immunisations with Vacc-4x (or placebo; fi gure 1). Participants received four primary immunisations, weekly for 4 weeks, with subsequent booster immunisations at weeks 16 and 18. After immunisation, participants remained on cART for another 10 weeks to allow time to reduce potential immune activation associated with immunisation. cART was stopped in eligible participants if their CD4 count was greater than 350 × 10⁶ cells per L and they were virally controlled (determined at week 24) such that all eligible participants were cART free at week 28. cART was resumed if CD4 counts fell below 350 × 10⁶ cells per L or decreased by greater than 50% compared with values at week 28, if viral load increased to greater than 300 000 copies per mL in two consecutive measurements, or if the participants developed any HIVrelated or AIDS-related events (CDC clinical category B or C). The criteria for restarting cART were based on the ACTG 5197 clinical study of the Merck adenovirus vectored preventive vaccine candidate Ad5. 12 The study period ended at week 52 with a long-term follow-up until week 104. Participants who resumed cART were followed up for an additional 24 weeks to ensure they regained virus control (<50 copies per mL). During the long-term follow-up, cART resumption was in accordance with local guidelines or agreement between the participant and the investigator.
Vacc-4x was manufactured by Bachem AG (Bubendorf, Switzerland), and distributed in vials by Penn Pharmaceutical Services Ltd (Gwent, UK). Vacc-4x (or placebo) was reconstituted in water on-site by pharmacists and given intradermally superfi cially to the left deltoid muscle at a dose of 0·1 mL of a 12 mg/mL solution about 10 min after giving adjuvant and immediately next to the adjuvant injection site. Sargramostim (recombinant human granulocyte-macrophage colony stimulating factor), provided as a marketed product by Berlex (Seattle, WA, USA), was used as a local adjuvant and injected intradermally at a dose of 0·1 mL of a 0·60 mg/mL solution. Placebo participants received water in place of both Vacc-4x and adjuvant.
CD4 and CD8 T-cell counts, viral load (Roche Ampliprep/COBAS TaqMan HIV-1), clinical chemistry, and haematology were done by Covance Laboratory Services in the USA (Indianapolis, IN, USA) and Europe (Geneva, Switzerland).
Since only one preART value was initially collected from participants' medical records, informed consent was subsequently given to collect a second value, where available in the records, taken within 6 months of the fi rst value. The preART viral-load setpoint was established as the mean of these two values where available. If a second value was not available, the single value was used. The viral-load setpoint (off ART) was the mean of a participant's fi nal two viral-load values before resumption of cART or at termination of the treatment interruption period-ie, week 52.
HIV-specifi c T-cell responses were assessed at certifi ed central laboratories from peripheral blood mononuclear cells prepared, cryopreserved, and shipped in liquid nitrogen from each participating site. All sites preparing the cells were accredited before the study start to ensure cells with recovery greater than 70% and viability greater than 80% on thawing.
Overlapping 15-mer peptides (off set by two aminoacids) for ELISPOT and proliferation were synthesised by Schafer-N (Copenhagen, Denmark). Interferon-γ ELISPOT analyses were done at the Division of Immunology and Allergy, Lausanne University Hospital (Lausanne, Switzerland) for all European samples and at UC Davis Immunology Specialty Laboratory (Sacramento, CA, USA) for all US samples as previously described 13 at weeks 1 (baseline), 6, 28, 44, and 52. Peripheral blood mononuclear cells were rested for 6 h after thawing and subsequently stimulated in triplicate wells in which the fi nal amount of each antigen was 1 μg per well (15-mer peptide pools of Vacc-4x peptides, 15-mer pool for p24
Gag corresponding to the same regions as Vacc-4x). Staphylococcal enterotoxin B (Sigma-Aldrich AG, St Louis, MO, USA) and media constituted positive and negative controls, respectively. Assays were deemed valid if the negative control had 50 spot forming units (SFU) per 10⁶ cells or fewer and the positive control had greater than 500 SFU per 10⁶ cells. An interferon-γ ELISPOT response was defi ned as positive if the triplicate test wells had a mean SFU four times or greater than the negative control and at least 55 SFU per 10⁶ cells. A participant was defi ned as a responder if there was at least one positive response against any of the antigens and a negative response at baseline or if the response was two times the baseline value or higher.
Ex-vivo T-cell proliferation analysis was done by use of a fl ow cytometry method at the Division of Immunology and Allergy, Lausanne University Hospital for all samples. After thawing and an overnight rest, peripheral blood mononuclear cells were labelled with 0·25 μmol/L 5,6-carboxy-fl uorescein diacetate suc cinimidyl ester (CFSE; Molecular Probes, Eugene, OR, USA) as described elsewhere 13, 14 and stimulated with Vacc-4x 15-mer or p24 Adverse events were recorded continuously throughout the study. Vital signs, physical examination, and clinical laboratory assessments were done at baseline and at selected timepoints throughout the study. The proportion of participants who regained virus suppression (<50 copies per mL) on cART resumption was assessed. Interleukin 6 measurements (eBioscience, San Diego, CA, USA) and detection of antibodies to recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF; USCN Life, Wuhan, China) were done by Bionor Laboratories (Skien, Norway). 
Outcomes
Coprimary efficacy objectives were to establish the proportion of participants who met the criteria for resumption of cART between the interruption of cART at week 28 and the end of the study at week 52 and percentage change in CD4 counts between week 28 (interruption of cART) and the last CD4 count assess ment before resumption of cART or week 52 if the participant did not resume cART in this period. Secondary effi cacy objectives were comparisons of time to restart of cART, changes in CD4 and CD8 counts, and changes in HIV RNA concentrations for Vacc-4x treated participants versus placebo. Immunogenicity was established with T-cell responses to Vacc-4x and p24
Gag regions corresponding to Vacc-4x, in peripheral blood mononuclear cells ex vivo by use of interferon-γ ELISPOT and T-cell proliferation.
Several additional exploratory analyses were done with only those participants in the modifi ed intention-to-treat (mITT) group (ie, all participants who received at least one intervention) who achieved a 6 month cART-free period from week 28 to study end (week 52). These were categorised as the off ARTwk52 subgroup.
Statistical analysis
This study was originally designed to enrol 345 participants to have a minimum of 90% power, for a two-sided test at the 5% signifi cance level with an assumed 15% non-evaluability rate, to detect a clinically relevant treatment diff erence of 20 percentage points for the primary endpoint proportion of participants who resumed cART between interruption of cART at week 28 and the end of the study at week 52 (assumed 40% Vacc-4x and 60% placebo participants needing to resume cART, which corresponds to an odds ratio [OR] of 0·44).
No sample sizing on participant subgroup outcomes was envisaged at the outset of the study. However, because of slow enrolment as a result of changing attitudes to clinical studies involving cART interruption by both patients and clinicians, particularly in view of the SMART study, 15 only 137 participants were actually enrolled. 135 of these participants provided the study population pool for the exploratory analyses. Under the same original sample sizing assumptions, but with only the reduced 135 participants (92 Vacc-4x, 43 placebo) the study power to detect the same clinically relevant treatment diff erence is reduced to 51%.
Statistical analyses were done with standard statistical software (SAS 9.2 and SPSS 17.0). All analyses compared treatment groups (Vacc-4x vs placebo) unless specifi cally stated otherwise, and analyses were done with two-sided hypothesis tests. Because of the midtrial decision to reduce the study sample size and because, on inspection, the viral-load data tended to be non-normal, a nonparametric analysis approach was selected to analyse viral-load endpoints.
Any data from participants after cART resumption were excluded from the effi cacy analyses. For the coprimary endpoints (analysis with all available participants) the proportion of participants who met the criteria for cART resumption was analysed with a logistic regression model with the treatment eff ect being assessed in a model including country as a covariate. Percentage change in CD4 count between week 28 (interruption of cART) and the last CD4 count assessment before cART resumption was analysed with ANOVA, including terms for treatment group and country in the model (data not shown).
For the secondary endpoint (analysis with all available participants) time to restart of cART was assessed by use of Kaplan-Meier estimation and the log-rank test (data not shown). Furthermore, viral load was analysed at each timepoint during the treatment interruption period using the Wilcoxon rank sum test.
For the exploratory analysis (off ARTwk52 subgroup) the viral-load setpoint, comparing treatment groups, was analysed with the Wilcoxon rank sum test. The viral-load setpoint was compared with the preART viral-load setpoint separately for each treatment group with the Wilcoxon signed rank test.
The proportion of interferon-γ ELISPOT responders to p24
Gag at any timepoint after baseline was compared between treatment groups with logistic regression, adjusting for the country where participants were enrolled (data not shown). Separate subgroup analyses of ELISPOT positive and negative responders at week 52 to p24
Gag were done, analysing the viral-load setpoint, comparing treatment groups using the Wilcoxon rank sum test. Furthermore, separately within each treatment group, positive and negative responders were similarly compared. This study is registered with ClinicalTrials.gov, number NCT00659789.
Role of the funding source
The sponsor of the study was involved in study design, data analysis, data interpretation, and writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
This study was done between July, 2008, and June, 2010; a 52 week follow-up period was completed in June, 2011 (fi gure 1). 136 participants were randomly assigned to receive study treatment (fi gure 2), but a withdrawal from the Vacc-4x group after randomisation left 135 in the in the placebo group one participant withdrew consent, one did not qualify for cART interruption, and one was lost to follow-up). 30 participants in the Vacc-4x group resumed cART between interruption of cART at week 28 and the end of the study at week 52 (34%) compared with 11 in the placebo group (29%; treatment diff erence OR 1·05, 95% CI 0·49-2·29; p=0·89). The 95% CI for the observed treatment diff erence OR crosses 1 and the lower limit is above the prespecifi ed (within original sample-size calculation) clinically meaningful treatment diff erence of 0·44. Therefore, the recorded treatment diff erence is not signifi cant and not clinically relevant. The reasons for restarting cART before week 52 for Vacc-4x versus placebo were because of AIDS-defi ning illness (one vs one), reduced CD4 count (15 vs eight), increase in viral load (two vs none), both CD4 and viralload responses (two vs none), patient or investigator decision (nine vs two), and lymphadenopathy in one Vacc-4x recipient. Similarly the time to return to cART was not diff erent (median 198 days in the Vacc-4x group vs 175 days in the placebo group; p=0·77). There was also no signifi cant diff erence in the percentage change in CD4 cell counts between week 28 (interruption of cART) and the last CD4 cell count assessment before cART resumption (mean treatment diff erence -5·71, 95% CI -13·01 to 1·59; p=0·12).
For viral load, there was a statistically signifi cant diff erence at weeks 48 (median 23 100 copies per mL in the Vacc-4x group vs 71 800 copies per mL in the placebo group; p=0·025) and 52 (median 19 550 copies per mL in the Vacc-4x group vs 51 000 copies per mL in the placebo group; p=0·041; fi gure 3).
Since not all participants achieved a 6 month cART-free period, the off ARTwk52 subgroup was used to compare viral-load setpoint at the end of the study period. There was a signifi cant reduction in median viral-load setpoint between Vacc-4x and placebo in the off ARTwk52 subgroup corresponding to a 0·44 log reduction (p=0·040; table 2).
When this analysis was extended to include all participants who remained off ART for at least 12 weeks (ie, until study week 40), the results show a non-signifi cant (p=0·149) diff erence between the study groups in viralload setpoint also favouring the vaccine (appendix).
PreART viral-load values were available for 63 participants in this subgroup. There was a signifi cant reduction in median viral-load setpoint compared with preART values in Vacc-4x participants in the off ARTwk52 subgroup (0·40 log reduction; p=0·0001). By contrast, the diff erence was not signifi cant for the placebo subgroup (0·02; p=0·98) where the viral-load setpoint returned to roughly preART levels (table 2) . The proportion of interferon-γ ELISPOT responders at any timepoint to p24
Gag (in the region spanning Vacc-4x) in Vacc-4x and placebo participants in the off ARTwk52 subgroup did not diff er between the two groups (data not shown). A signifi cant diff erence in viral-load setpoint between interferon-γ ELISPOT responders to p24
Gag in the Vacc-4x and placebo groups was noted in the off ARTwk52 subgroup (median 13 425 copies per mL in the Vacc-4x group vs 76 600 copies per mL in the placebo group; p=0·022; fi gure 4). For the non-responders, the diff erence was not signifi cant (median 19 650 copies per mL in the Vacc-4x group vs 30 000 copies per mL in the placebo group; p=0·82). Furthermore, there were no signifi cant diff erences when comparing responders with non-responders for the Vacc-4x group (p=0·70), and separately comparing responders with non-responders for the placebo group (p=0·17).
We assessed the proliferative capacity of HIV-specifi c CD4 and CD8 T cells after ; fi gure 5). The T-cell proliferative assay responses to p24 antigens were reasonably sustained over the study period (fi gure 5).
Vacc-4x was safe and well tolerated (ITT population). The proportion of patients with adverse events described as "at least probably related to treatment" was greater in the Vacc-4x (81/93; 87%) than the placebo group (24/42; 57%). The diff erence was chiefl y attributable to a higher rate of injection-site reactions (most commonly injection site erythema, induration, or pruritus); the adverse event profi le was otherwise similar between the groups. A total of nine serious adverse events were recorded, fi ve of which were in the Vacc-4x group. One serious adverse event, exacerbation of multiple sclerosis, was classifi ed as possibly related to study treatment. One placebo participant died from myocardial infarction at week 43 while off cART. When participants resumed their original cART regimens, they responded well to reinitiation, and were well controlled (viral load <50 copies). Interleukin 6 concentrations remained within normal range, or showed no increase between baseline and week 52 (two participants displayed a fourtimes increase between baseline and week 52). No elevation in anti-GM-CSF antibody titre between baseline and week 6 was noted for the fi rst 20 participants (no participants achieved a four-times increase between baseline and week 6) and was therefore not assessed for the remaining participants.
Discussion
Despite no diff erences between the Vacc-4x and placebo groups for the coprimary effi cacy endpoints (cART resumption and changes in CD4 count over time), there was a signifi cant reduction in viral load in the Vacc-4x group compared with placebo at the last two timepoints during cART interruption. Additional exploratory analyses were done on the subgroup of patients who successfully remained off cART for the full 24 week period. This off ARTwk52 subgroup analysis showed a signifi cant reduction in viral-load setpoint in the Vacc-4x group compared with placebo and a highly signifi cant reduction in viral-load setpoint from historical preART values. By contrast, the viral-load setpoint for participants in the placebo group was generally the same or higher than their preART value, similar to other studies when cART is interrupted in the absence of a therapeutic intervention. 16 Of note, preART viral-load values were higher in the Vacc-4x compared with placebo groups.
GM-CSF was used as a local adjuvant in this study. It was not used in the placebo group because of a suggestion from the FDA to use a true placebo in the trial. The potential direct eff ects of GM-CSF in HIV infection have been investigated in several studies, results from which have varied, from favourable eff ects on plasma viral load to increases in plasma viral load. 17, 18 Accounting for the substantially lower dose, diff erent route of administration, and the 10 week interval from the last dose of GM-CSF to initiation of the treatment interruption, it is highly unlikely that GM-CSF has had an eff ect on the study outcomes.
T-cell responses were measured ex vivo using interferon-γ ELISPOT and proliferation. Since Vacc-4x aims to improve immune responses to immunologically vulnerable conserved domains on HIV-1 p24 Gag , responses to these conserved regions were our major focus. T-cell responses were noted to increase at weeks 44 and 52 (off ART) as a result of viral rebound. However, the observation that ELISPOT responders at week 52 in the Vacc-4x group had a lower viral-load setpoint than ELISPOT responders in the placebo group suggests a potential qualitative diff erence in the vaccine-induced immune response similar to that reported in earlier studies (panel). 5, 37 Findings from the previous Vacc-4x phase 2 study showed very low immune escape in these conserved regions in participants who had received Vacc-4x. 38 Vacc-4x induced proliferative responses in both CD4 and CD8 T-cell subsets, while there was no corresponding increase in T-cell proliferation in the placebo group. Further analysis will be needed to establish whether a responder profi le can be characterised and a surrogate marker identifi ed for favourable outcome.
Vacc-4x was generally safe and well tolerated. Treatment interruption was well tolerated in most participants, in agreement with other therapeutic vaccine and treatment interruption trials. 5, 15, 19, 20 However, one placebo recipient did experience a fatal myocardial infarction during cART interruption, which the investigator could not exclude as possibly related to study participation since previous studies have linked cART interruption to increased levels of infl ammation and increased risk of cardiovascular events; 15 however, the measured infl ammatory marker (high-sensitivity C-reactive protein) was not raised in this case.
Our study has several limitations. It is recognised that because of the smaller number of recruited participants than originally planned (137 vs 345) and the use of additional analyses, done on a subgroup of participants who achieved a 52 week off -ART period, these data need to be considered as exploratory. It was considered to increase the number of clinical trial sites to improve the
Panel: Research in context
Systematic review On Aug 4, 2013, we searched PubMed for reports published at any time previously, with the term "HIV vaccine trial viral-load treatment interruption". 20 published reports of clinical trials assessing various HIV therapeutic vaccine approaches, all of which included a "structured" or "analytical" cART interruption phase, were identifi ed. 4, 5, 11, 12, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] These investigations have included various HIV-specifi c peptide approaches delivered either directly or through viral vectors (eg, adenovirus, canarypox, fowl pox, modifi ed vaccinia Ankara), DNA plasmids, or even as peptide loaded dendritic cells. Many of these clinical studies have been done in small sample sizes (ie, ≤30 participants), 19, 21, 24, 26, 27, 29, 33, 34, 36 and often in a non-controlled manner, 11, 21, 24, 33, 34 making defi nitive conclusions diffi cult. Very few investigators have been able to correlate specifi c vaccine-induced immune responses with viral-load outcomes. 5, 11 Indeed some have reported signifi cant immunogenicity leading to higher viral rebound after cART interruption. 28 One of the most promising approaches recently reported is that of Felipe GarcÍa and colleagues, 5 who created an HIV-specifi c therapeutic vaccine by modifying patients' own dendritic cells. They showed that 12 weeks after cART interruption, a decrease of plasma viral-load setpoint of 1 log or greater was noted in 12 of 22 patients (55%) in the vaccinated group versus one of 11 (9%) in the control group, and, at 24 weeks interruption, in seven of 20 (35%) in the vaccinated group versus none of ten in the control group. This substantial decrease in plasma viral load was associated with increases in HIV-1-specifi c T-cell responses but waned over time. Also the broad applicability of a designer therapeutic vaccine approach remains to be realised.
Interpretation
We have successfully completed a large, randomised, placebo-controlled clinical trial to assess Vacc-4x. We have shown that Vacc-4x, a peptide-based therapeutic vaccine designed to improve and sustain immune responses to conserved domains on the HIV-1 core protein p24 Gag , is one of the few HIV therapeutic vaccines assessed so far that seems to induce proliferative responses in both CD4 and CD8 T-cell populations and contribute to a viral-load reduction after cART interruption for up to 24 weeks. Our fi ndings suggest that Vacc-4x could be further investigated as an important component of a broader HIV cure strategy because it is now recognised that present eff orts to purge the HIV viral reservoirs fail to reduce HIV-1 persistence. 4 By boosting HIV-1-specifi c cytotoxic T lymphocytes before reactivating latently HIV-infected cells it is thought possible to achieve reductions in HIV-1 viral reservoirs allowing functional cure of HIV infection. recruitment rate; however, feedback from participating clinical investigators and the study sponsors made the feasibility and probable success of achieving complete recruitment within a reasonable timeframe unlikely, in view of the climate after the release of the SMART data. A protracted recruitment phase might also have resulted in study population diff erences, which might have aff ected the analysis. It was therefore agreed with regulatory agencies that redefi ning the study as exploratory would allow several hypothesis-generating analyses to be done.
The downsizing of the study cohort compared with the original plan made it more diffi cult to capture treatmentrelated eff ects. Despite this, the study remains one of the largest controlled clinical trials assessing an HIV therapeutic vaccine and the data described here provide valuable information on Vacc-4x. Even if the rate of cART resumption during the treatment interruption period was balanced between the two groups, this attrition might have introduced a selection bias favouring better outcomes that needs to be considered when interpreting the data.
In conclusion, we believe the study reported here provides initial proof of concept to support a role for therapeutic HIV vaccines, since the fi nding that Vacc-4x is immunogenic and capable of changing plasma viralload setpoint after an analytical treatment interruption of cART. The mechanism behind this apparent eff ect remains to be elucidated, but the results accord with other studies, which have shown that immune responses to conserved regions of p24 are associated with better viral control. Therapeutic vaccines, such as Vacc-4x, might have a future role in complementing cART regimens, to improve or sustain HIV-specifi c immune responses and control viral load. Furthermore, there is now a growing interest in the potential contribution of therapeutic vaccination to aid functional cure through combination with histone deacetylase inhibitors, which have the potential to reactivate virus replication from the latent pool and thus generate CD4 T cells expressing HIV antigens that might serve as a target to the T-cell response enhanced by therapeutic vaccination. 3, 4 With either approach, thera peutic vaccination would need to result in greater and more sustained viral-load reductions than that shown by candidate therapeutic vaccines so far. It remains to be established whether viral load can be reduced even further if Vacc-4x is combined with o ther interventions or after reboosting and a second treatment interruption. Such assessments are underway at present (registered with ClinicalTrials.gov, numbers NCT01704781 and NCT01712256).
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